Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

about

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.

P2860

Q38822920-A5BE72CC-268B-4BB8-BBD0-9A8916ABDC44 Q48136341-B8C8CB58-DDAC-4D35-AB26-37311C857662

P2860

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

Item

http://www.wikidata.org/entity/Q40868226

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Infliximab Dose Escalation as ...... esponse in Ulcerative Colitis.

@en

type

Item

label

Infliximab Dose Escalation as ...... esponse in Ulcerative Colitis.

@en

prefLabel

Infliximab Dose Escalation as ...... esponse in Ulcerative Colitis.

@en

P1476

Infliximab Dose Escalation as ...... Response in Ulcerative Colitis

@en

P2093

Carlos Taxonera

http://www.w3.org/2001/XMLSchema#string

Celia de Gracia

http://www.w3.org/2001/XMLSchema#string

Cristina Alba

http://www.w3.org/2001/XMLSchema#string

Cristina Saro

http://www.w3.org/2001/XMLSchema#string

David Olivares

http://www.w3.org/2001/XMLSchema#string

Fernando Bermejo

http://www.w3.org/2001/XMLSchema#string

Ignacio Fernández-Blanco

http://www.w3.org/2001/XMLSchema#string

Ignacio Marín-Jiménez

http://www.w3.org/2001/XMLSchema#string

Juan L Mendoza

http://www.w3.org/2001/XMLSchema#string

Manuel Barreiro-de Acosta

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

P2888

s10620-015-3735-4

P304

3075-3084

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-015-3735-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26044830

http://www.w3.org/2001/XMLSchema#string

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

about

P2860

P2860

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698